Staphylococcus aureus | Current projects
CAMERA2 - combination antibiotic therapy for methicillin-resistant Staphylococcus aureus infection
Methicillin-resistant Staphylococcus aureus (MRSA) bloodstream infection is a serious infection resulting in 20-50 % 90-day mortality. Current therapies are limited. Our aim is to determine whether the addition of an anti-staphylococcal penicillin to standard therapy results in improved clinical outcomes in MRSA bacteraemia. We will perform an open-label, parallel-group, randomised controlled trial comparing standard therapy to standard therapy plus 7 days of an anti-staphylococcal b-lactam.